Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

EGRX

Rank in Stocks #28490
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on... Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Share Price
$0.82
Last synced: 2026-11-10
Market Cap
$10.73M
Change (1 day)
228.00%
Change (1 year)
-36.92%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Trade Eagle Pharmaceuticals, Inc. (EGRX)

Category

Healthcare
EPS for Eagle Pharmaceuticals, Inc. (EGRX)
EPS as of June 2023 TTM: $1.19
According to Eagle Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $1.19. At the end of 2022 the company had an EPS of $2.76, an increase over its 2021 EPS of $-0.66.
EPS history for Eagle Pharmaceuticals, Inc. from 2012 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $1.19 -56.88%
2022 $2.76 -518.18%
2021 $-0.66 -174.16%
2020 $0.89 -14.42%
2019 $1.04 -51.85%
2018 $2.16 -37.21%
2017 $3.44 -34.35%
2016 $5.24 2,982.35%
2015 $0.17 -109.39%
2014 $-1.81 217.54%
2013 $-0.57 -68.85%
2012 $-1.83 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 406.71%
DE
$6.01 404.86%
DE
$1.53 28.82%
JP
$3.66 207.56%
CH
$0.45 -62.18%
IL

Questions about Eagle Pharmaceuticals, Inc.'s earnings per share (EPS)

What is Eagle Pharmaceuticals, Inc.'s earnings per share (EPS)?

Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $1.19, as of Jun 2023.

What was Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) in 2022?

In 2022, Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) was $2.76, compared with $-0.66 in 2021.

How has Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2017?

From 2017 to 2022, Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) went from $3.44 to $2.76, an average decline of 4.31% a year.

How does Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?

Eagle Pharmaceuticals, Inc.'s earnings per share (EPS) ($1.19) is higher than that of 1 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.